Impact of first‐line infliximab on the pharmacokinetics of second‐line vedolizumab in inflammatory bowel diseases-Reference-Cited by-同舟云学术

Impact of first‐line infliximab on the pharmacokinetics of second‐line vedolizumab in inflammatory bowel diseases

Author:

Liefferinckx Claire¹²^ORCID,Verstockt Bram³⁴^ORCID,Gils Ann⁵,Tops Sophie⁵,Van Moerkercke Wouter³⁶,Vermeire Severine³⁴,Franchimont Denis¹²

Affiliation:

1. Department of GastroenterologyHôpital ErasmeULBBrusselsBelgium

2. Laboratoire de gastroenterology experimentaleULBBrusselsBelgium

3. University Hospitals LeuvenDepartment of Gastroenterology and HepatologyLeuvenBelgium

4. KU LeuvenDepartment of Chronic Diseases, Metabolism and AgeingLeuvenBelgium

5. Department of Pharmaceutical and Pharmacological SciencesKU LeuvenBelgium

6. Department of GastroenterologyAZ GroeningeKortrijkBelgium

Funder

Fonds Wetenschappelijk Onderzoek

Bourse conseil médical

Publisher

Wiley

Subject

Gastroenterology,Oncology

Link

Reference22 articles.

1. What to do when biologic agents are not working in inflammatory bowel disease patients;Dalal SR;Gastroenterol Hepatol (N Y),2015

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献